In conclusion, Engeletin emerges as a novel multitarget therapeutic agent for IBD by restoring mitochondrial homeostasis and suppressing epithelial apoptosis via AMPK/SIRT1/PGC-1α signaling. Here, SIRT1 is linked to inflammatory bowel disease.